Several biotech firms and academic researchers report advancements integrating AI and CRISPR technologies. Goodpath secured $18 million to expand its chronic condition AI platform, while VedaBio licensed Mammoth Biosciences’ diagnostic CRISPR IP to reduce costs and turnaround times in point-of-care testing. Additionally, a study highlights AI’s power designing innovative peptides for therapeutics. The collaborative integration of AI-driven analytics and gene editing underlines a transformative shift in biotechnology research and clinical applications.